Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 306 participants.

Also called NCT01524289

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 306 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01524289
  • EudraCT 2011-004525-27
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01524289. Randomized; double masking; primary purpose treatment. Start 2012-02-03 (actual); primary completion 2014-02-12 (actual). Results posted on 2019-08-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
Acronym
REALIZE
Condition
Hyperlipoproteinemia Type II
Condition
Hypercholesterolemia, Familial
Intervention (Drug)
Anacetrapib
Intervention (Drug)
Placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01524289
Content hash
a2f5b1927c808a1a769a016d6195f9fa19793f0e516ee545af05f898642a8bc9